Sign In
Buy CRSP
$48.15
+1.16 (+2.47%)
At Close: Jul 21, 2026
Ready to Buy the Dip? CRISPR Therapeutics Stock Is a Smart Buy
09:45am, Friday, 11'th Aug 2023
CRISPR Therapeutics stock took a beating in the bear market. It now has two attempts to commercialize its exa-cel therapy.
The 3 Best Biotech Stocks to Buy in August
04:00pm, Wednesday, 09'th Aug 2023
Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus' spread. But medical innovations and technological breakthroughs are rapidly transforming the health
2 Great Stocks Under $100 to Buy and Hold for 10 Years
09:30am, Wednesday, 09'th Aug 2023
CRISPR Therapeutics is using an award-winning technology to develop breakthrough therapies. Block's ecosystems, which target both individuals and businesses, have seen growing success.
Why CRISPR Therapeutics Stock Is Jumping Today
12:14pm, Tuesday, 08'th Aug 2023
CRISPR Therapeutics topped consensus estimates with its Q2 results. Two analysts issued positive updates for the stock.
3 Biotech Stocks That Analysts Are Drooling Over
06:57pm, Monday, 07'th Aug 2023
With everyone being an expert these days, the concept of top analyst biotech picks might seem suspect at first glance. While we depend on Wall Street's spectrum of expert guidance to establish a frame
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates
06:54pm, Monday, 07'th Aug 2023
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $2.18. This compares to loss of $2.40 per share a year ago.
CRISPR (CRSP) to Post Q2 Earnings: What's in the Offing?
12:08pm, Monday, 07'th Aug 2023
CRISPR (CRSP) currently does not have any marketed product in its portfolio. The company is expected to provide regulatory updates on exa-cel applications, along with other pipeline updates.
3 ‘Strong Buy' Biotech Stocks You Should Be Loading Up On Now
03:17pm, Wednesday, 02'nd Aug 2023
Medical stocks, in general, aren't enjoying the market-wide reversal we're seeing in the back half of 2023. The Morningstar US Healthcare Index, which measures a range of biotech, pharma, medical devi
This 1 Innovation Could Make These 2 Biotechs Soar by 2030
09:45am, Saturday, 22'nd Jul 2023
It's cumbersome and costly to manufacture complicated cell therapies. Caribou Biosciences and CRISPR Therapeutics have a better way of doing things.
Is Now a Good Time to Buy CRISPR Therapeutics?
05:30am, Friday, 21'st Jul 2023
CRISPR Therapeutics expects regulatory decisions soon for what would be its first commercialized product. An approval would represent a vote of confidence in the technology CRISPR uses throughout its
Cathie Wood Is Buying These 3 Growth Stocks Hand Over Fist. Should You?
05:14am, Saturday, 15'th Jul 2023
Cathie Wood recently added more than a million shares of a synthetic biology company called Ginkgo Bioworks to the Ark Innovation ETF. PagerDuty's automated tech-support platform is a hit with big ent
2 No-Brainer Healthcare Stocks to Buy With $100 Right Now
09:30am, Thursday, 13'th Jul 2023
CRISPR Therapeutics could soon have an approved gene-editing therapy it can price at over $1 million. CVS Health's expanding business makes it a relatively safe investment with tons of growth potentia
3 Biotech Stocks to Buy for Long-Term Gains
07:01am, Thursday, 13'th Jul 2023
Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated
2 Top Healthcare Stocks Defying the Bear Market
06:00am, Tuesday, 11'th Jul 2023
CRISPR Therapeutics is awaiting a regulatory decision on what may become its first commercialized product. Intuitive's revenue model and market leadership make it a top long-term stock to own.
3 Growth Stocks With 55% to 71% Upside, According to Wall Street
05:21am, Sunday, 09'th Jul 2023
The way Americans watch local sports is changing fast, and FuboTV is positioned to benefit. CRISPR Therapeutics is developing gene therapies, and its first product could earn approval before the end o
